Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China

Kong, Linghong; Xie, Xiaoxin; Fu, Yanhua; Gan, Lin; Yang, Xiaoyan; Ma, Shujing; Long, Hai

doi:10.1002/iid3.974

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ongoing research, open provider-patient communication, and appropriate regulation are critical [64,65].…”

Section: Safety Efficacy and Drug Interactionsmentioning

confidence: 99%

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

Addissouky,

El Tantawy El Sayed,

Ali

et al. 2024

J AIDS HIV Treat

View full text Add to dashboard Cite

Background: HIV/AIDS remains a major global public health challenge despite significant progress in treatment. New infections and HIV-related deaths persist, fueled by disparities in prevention and care access. Purpose: This review synthesizes recent advances across key domains - from vaccine development to novel treatments to omics approaches – that collectively hold promise for ending the HIV/AIDS pandemic. Main body: Multiple innovative HIV vaccine platforms are now in early-phase trials, including mRNA vaccines as well as conserved epitope and mosaic constructs for broader immunogenicity. Long-acting injectable antiretrovirals represent a major milestone in HIV treatment, while gene editing techniques offer future curative potential. Leveraging multi-omics data through genomics, transcriptomics, proteomics, and metabolomics provides systems-level insights into viral persistence and new therapeutic opportunities. The gut microbiome is increasingly recognized as a mediator of HIV progression, spurring research into probiotic/prebiotic supplementation and fecal transplantation. Across these domains, integration of artificial intelligence and machine learning will likely accelerate discovery. Conclusion: Despite past setbacks, the HIV cure effort has renewed momentum. Translating emerging tools like long-acting antiretrovirals and omics profiling into broader clinical application could bend the pandemic’s trajectory. Innovation must be paired with ensuring equitable access to maximize global impact.

show abstract

“…Ongoing research, open provider-patient communication, and appropriate regulation are critical [64,65].…”

Section: Safety Efficacy and Drug Interactionsmentioning

confidence: 99%

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

Addissouky,

El Tantawy El Sayed,

Ali

et al. 2024

J AIDS HIV Treat

View full text Add to dashboard Cite

show abstract

Measuring the health-related quality of life in HIV patients with integrase strand transfer inhibitor-based regimens in China

Tang,

Huang,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background With bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), and dolutegravir/lamivudine (DTG/3TC) included in the national drug reimbursement list, the integrase strand transfer inhibitor (INSTI)-based regimens could be afforded and used by more patients. Majority of previous health-related quality of life (HRQoL) studies were conducted before INSTI-based regimens reimbursed and have no restriction on the regimens received. The aim of the study is to measure the HRQoL of HIV patients with INSTI-based regimens in China. Methods A cross-sectional survey of HIV patients conducted in the First Hospital of Changsha. Adult patients diagnosed with HIV-1 infection between January 1st, 2021-July 31st, 2022, with the prescription of BIC/FTC/3TC or DTG/3TC as the current treatment were included. Patients’ responses were collected through a digital platform and the HRQoL were measured by three questionnaires, including HIV-symptom index (HIV-SI) questionnaire, Patient Health Questionnaire‐9 (PHQ-9) and the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L). Generalized linear regression model was used to estimate the effects of covariates on each HRQoL measure. Results A total of 143 HIV patients with HRQoL data available were included in the study. The mean (SD) of HIV-SI total score, PHQ-9 total score and EQ-5D utility score was 26.7 (14.4), 7.4 (1.0) and 0.95 (0.12), respectively. Compared with treatment-naive patients, treatment-experienced patients reported significantly higher score/proportion of HIV-SI and PHQ-9 total score, presence of depression and problems in anxiety/depression (all p<0.05). Patients with older age, without formal work, having treatment switch due to safety reason and lower CD4 cell counts had significantly higher HIV symptom burden and worse depression status, respectively (all p<0.05). Conclusions HIV patients suffer from HIV symptoms and depression, which greatly deteriorate their HRQoL. Considering the aging population and lower employment rate, the needs for social support or patient-assistant program for HIV patients are highlighted. The early initiation of INSTI-based regimens is necessary to avoid the HRQoL loss due to safety reasons.

show abstract

Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China

Cited by 2 publications

References 17 publications

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

Bending the Curve Through Innovations to Overcome Persistent Obstacles in HIV Prevention and Treatment

Measuring the health-related quality of life in HIV patients with integrase strand transfer inhibitor-based regimens in China

Contact Info

Product

Resources

About